PHI News Room
All News and Press Releases
Enter any phrase or word you would like to search for and click .
PostNews
BioStock: PHI grows its network of collaborations
BioStock caught up with PHI’s CEO Patrik Eschricht to ask about his outlook for the growing number of academic collaborations and sales partnerships.
PostNews: Press Release
PHI bolsters Nordic sales presence with new distribution agreement between Altium and Kem-En-Tec Nordic
PHI is pleased to announce a new distribution agreement between its global distribution partner, Altium, and Kem-En-Tec Nordic, a lab supplier dedicated to supporting BioScience labs in Denmark, Sweden, Norway, Finland and Iceland.
PostNews: Press Release
PHI expands to Spanish and Portuguese markets through Altium’s new subcontract with Paralab
PHI is pleased to announce a strategic expansion into the Spanish and Portuguese markets, facilitated by a new subcontract between its global distribution partner, Altium, and Paralab.
PostNews: Press Release
PHI partners with University College London to use HoloMonitor in a first clinical research project
PHI is excited to announce a strategic partnership with University College London (UCL). Under this collaboration, PHI will lend a HoloMonitor® M4FL system for use in an ongoing research project at UCL, which runs alongside a clinical trial. This partnership represents PHI’s first direct step in a hospital setting to explore the clinical applications of its innovative technology.
PostNews: Press Release
PHI terminates agreement regarding liquidity provider
PHI today announces that the Company has terminated the liquidity provider agreement with Pareto Securities AB. The agreement will expire on July 31, 2024.
PostNews
BioStock: PHI “It’s the right moment to capitalize on regenerative medicine momentum.”
BioStock contacted CEO Patrik Eschricht for an update on the company’s progress and how PHI will capitalize on the current momentum.
Company News
Here, you see PHI featured in recent news and find previous CEO commentaries.
New CEO commentary — “Redefining aging with HoloMonitor”
In the CEO commentary “Redefining aging with HoloMonitor” Peter Egelberg comments on the promising research results that were recently reported by Australian television.
New CEO commentary: “The scientific role of commercialization”
On PHI’s website, founder and CEO Peter Egelberg comments on his presentation at SPIE 2018 in San Francisco “The evolution of Phase Holographic Imaging from a research idea to publicly traded company”, see CEO commentary The scientific role of commercialization, published February 18, 2018.
Life is a mess
In our daily lives, we all know how important it is to plan ahead to avoid a future mess. Ironically, we ourselves are such a future mess.
Fighting cancer with nanoparticles
Using HoloMonitor, scientists at Northeastern University have shown that paclitaxel-resistant ovarian cancer cells stopped multiplying by cell division when treated with nanoparticles. Ovarian cancer causes more deaths than any other cancer of the female reproductive system.
